As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Astria Therapeutics, Inc. The largest reported stake is Glazer Capital, LLC's, at 6.61%. 14 filings are on record since August 14, 2025 (Schedule 13G/A, February 12, 2026).
Sell to companies like Astria Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Vestal Point Capital, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Glazer Capital, LLC · Percent: 6.61% · SCHEDULE 13G/A
- · Holder: Perceptive Advisors LLC · Percent: 0% · SCHEDULE 13D/A
- · Holder: Magnetar Financial LLC · Percent: 0% · SCHEDULE 13D/A
- · Holder: Glazer Capital, LLC · Percent: 5.53% · SCHEDULE 13G
Astria Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Glazer Capital, LLC | 6.61% | 3,776,154 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Fairmount Funds Management LLC | 4% | 2,377,049 | SCHEDULE 13G/A, 2025-10-15 | 2025-10-14 |
| Fmr LLC | 2.2% | 1,251,766 | SCHEDULE 13G/A, 2025-11-07 | 2025-10-31 |
| Millennium Management LLC | 0.4% | 222,101 | SCHEDULE 13G/A, 2025-10-20 | 2025-10-14 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Perceptive Advisors LLC | 0% | 0 | SCHEDULE 13D/A, 2026-02-09 | 2026-01-26 |
| Magnetar Financial LLC | 0% | 0 | SCHEDULE 13D/A, 2026-01-28 | 2026-01-26 |
| Vestal Point Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| ForGrowth III PA B.V. | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-10-16 |
Holding shares or following this stake? See who's behind Astria Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Astria Therapeutics, Inc. and the records around it.
Companies that share a holder
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Astria Therapeutics, Inc.
Get an email when Astria Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Astria Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Astria Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Astria Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Perceptive Advisors LLC
The Reporting Persons' beneficial ownership in the Issuer changed as a result of the consummation of the previously announced acquisition of the Issuer by BioCryst pursuant to the Merger Agreement . The Merger was completed on January 23, 2026, and the Issuer ceased to exist as a separate entity. As a result of the merger, the Reporting Persons no longer beneficially owns any shares of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-02-09
Magnetar Financial LLC
Since the filing of the Schedule 13D on October 24, 2025, on January 23, 2026, the Issuer consummated a merger (the "Merger") pursuant to which each issued and outstanding Share was cancelled and converted into the right to receive $8.55 in cash, without interest. In connection with the Merger, the Reporting Persons' 3,431,007 Shares, which consisted of 1,560,502 Shares sold for the benefit of PRA Master Fund; 804,159 Shares sold for the benefit of Systematic Master Fund; 221,576 Shares sold for the benefit of the Relative Value Master Fund and 844,770 Shares sold for the benefit of two Managed Accounts, were cancelled and converted into the right to receive $8.55 in cash, without interest.Item 4 of the SCHEDULE 13D/A filed 2026-01-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2025-10-15 | Fairmount Funds Management LLC | 4% | SCHEDULE 13G/A |
| 2025-10-16 | Perceptive Advisors LLC | 11.5% | SCHEDULE 13D/A |
| 2025-10-20 | Millennium Management LLC | 0.4% | SCHEDULE 13G/A |
| 2025-10-24 | Magnetar Financial LLC | 5.87% | SCHEDULE 13D |
| 2025-11-05 | Fmr LLC | 9.1% | SCHEDULE 13G/A |
| 2025-11-07 | Fmr LLC | 2.2% | SCHEDULE 13G/A |
| 2025-11-14 | Vestal Point Capital, LP | 8.8% | SCHEDULE 13G/A |
| 2025-11-14 | ForGrowth III PA B.V. | 0% | SCHEDULE 13G/A |
| 2025-12-10 | Glazer Capital, LLC | 5.53% | SCHEDULE 13G |
| 2026-01-28 | Magnetar Financial LLC | 0% | SCHEDULE 13D/A |
| 2026-02-09 | Perceptive Advisors LLC | 0% | SCHEDULE 13D/A |
| 2026-02-12 | Glazer Capital, LLC | 6.61% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 0% | SCHEDULE 13G/A |
Questions about who owns Astria Therapeutics, Inc.
Who owns Astria Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Astria Therapeutics, Inc.: Glazer Capital, LLC (6.61%, Schedule 13G/A, filed 2026-02-12).
When did Glazer Capital, LLC buy into Astria Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Glazer Capital, LLC on this page is the Schedule 13G, filed 2025-12-10, reporting 5.53%; its latest, Schedule 13G/A filed 2026-02-12, reports 6.61%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Astria Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.